SEC Form 4 · accession 0001553878-17-000047
ALNYLAM PHARMACEUTICALS, INC. · ALNY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Barry E Greene
Officer — President
Period of report
Sep 20, 2017
Accepted (ET)
Sep 22, 2017 · 5:05 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178670
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 20, 2017 | M | 76,815 | $31.39 | A | 165,399 | D | |
| Common Stock | Sep 20, 2017 | S | 76,815 | $100.00 | D | 88,584 | D | |
| Common Stock | Sep 21, 2017 | M | 6,485 | $7.10 | A | 95,069 | D | |
| Common Stock | Sep 21, 2017 | M | 5,359 | $18.66 | A | 100,428 | D | |
| Common StockF2 | holding | — | — | — | 2,810 | I | By Managed Account |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Performance Stock Option 2013 (Right to Buy) | $63.00 | Sep 20, 2017 | A | 15,000 | A | Sep 20, 2017 | Dec 17, 2023 | Common Stock | 15,000 | 15,000 | D |
| Stock Option (Right to Buy)F4 | $7.10 | Sep 21, 2017 | M | 6,485 | D | — | Nov 30, 2021 | Common Stock | 6,485 | 85,915 | D |
| Stock Option (Right to Buy)F4 | $18.66 | Sep 21, 2017 | M | 5,359 | D | — | Dec 20, 2022 | Common Stock | 5,359 | 94,641 | D |
| Stock Option (Right to Buy)F4,F1 | $31.39 | Sep 20, 2017 | M | 76,815 | D | — | Dec 12, 2017 | Common Stock | 76,815 | 0 | D |
Explanation of responses
- F1The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 23, 2017. The 76,815 options exercised and sold by the reporting person were due to expire on December 12, 2017.
- F2The reporting person owns 2,810 shares of ALNY common stock under the ALNY 401(k) plan as a result of the ALNY 401(k) matching contribution program.
- F3On December 18, 2013, the reporting person was granted a performance based stock option to purchase shares of ALNY Common Stock. One-third of the shares subject to the option will vest upon the achievement of each of three specific clinical development and regulatory events, as approved by the compensation committee of the Company. Effective September 20, 2017, the compensation committee of the Company determined the second performance criteria had been met and the option was vested as to one-third of the shares.
- F4The stock option vests as to 25% of the shares on the first anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter.